Barrington Research Issues Pessimistic Forecast for Orthofix Medical (NASDAQ:OFIX) Stock Price

Orthofix Medical (NASDAQ:OFIX) had its price target lowered by equities research analysts at Barrington Research from $18.00 to $17.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the medical device company’s stock. Barrington Research’s price objective would indicate a potential upside of 29.08% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on OFIX. Weiss Ratings restated a “sell (d-)” rating on shares of Orthofix Medical in a report on Thursday, January 22nd. Stifel Nicolaus started coverage on shares of Orthofix Medical in a research report on Tuesday, October 28th. They issued a “buy” rating and a $22.00 price target on the stock. Finally, TD Cowen assumed coverage on shares of Orthofix Medical in a report on Tuesday, January 27th. They set a “hold” rating and a $14.00 price objective for the company. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $18.25.

Orthofix Medical Price Performance

OFIX opened at $13.17 on Wednesday. The company has a fifty day moving average price of $14.12 and a two-hundred day moving average price of $14.70. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.38 and a current ratio of 2.45. Orthofix Medical has a 52 week low of $10.24 and a 52 week high of $18.66. The firm has a market capitalization of $521.53 million, a PE ratio of -5.63 and a beta of 0.78.

Orthofix Medical (NASDAQ:OFIX) last posted its quarterly earnings results on Tuesday, February 24th. The medical device company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $0.44 by ($0.50). Orthofix Medical had a negative net margin of 11.21% and a negative return on equity of 20.38%. The company had revenue of $219.91 million during the quarter, compared to analyst estimates of $218.72 million. As a group, analysts anticipate that Orthofix Medical will post -2.81 earnings per share for the current year.

Insider Buying and Selling at Orthofix Medical

In related news, major shareholder Engine Capital Management, Lp purchased 13,061 shares of Orthofix Medical stock in a transaction that occurred on Wednesday, February 25th. The stock was purchased at an average cost of $12.96 per share, with a total value of $169,270.56. Following the completion of the transaction, the insider owned 3,673,092 shares of the company’s stock, valued at approximately $47,603,272.32. This trade represents a 0.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Julie Andrews sold 4,873 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $14.38, for a total value of $70,073.74. Following the completion of the transaction, the chief financial officer owned 58,039 shares of the company’s stock, valued at approximately $834,600.82. This represents a 7.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 24,270 shares of company stock worth $370,958. Insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On Orthofix Medical

Several large investors have recently made changes to their positions in OFIX. AYAL Capital Advisors Ltd grew its stake in Orthofix Medical by 74.7% in the 2nd quarter. AYAL Capital Advisors Ltd now owns 943,203 shares of the medical device company’s stock valued at $10,517,000 after buying an additional 403,433 shares during the last quarter. Squarepoint Ops LLC grew its position in shares of Orthofix Medical by 515.6% in the second quarter. Squarepoint Ops LLC now owns 117,666 shares of the medical device company’s stock valued at $1,312,000 after purchasing an additional 98,552 shares during the last quarter. Engine Capital Management LP increased its stake in shares of Orthofix Medical by 13.6% during the second quarter. Engine Capital Management LP now owns 4,251,671 shares of the medical device company’s stock worth $47,406,000 after purchasing an additional 510,281 shares during the period. Geode Capital Management LLC lifted its holdings in Orthofix Medical by 7.5% during the 2nd quarter. Geode Capital Management LLC now owns 930,252 shares of the medical device company’s stock worth $10,374,000 after purchasing an additional 64,788 shares during the last quarter. Finally, Bastion Asset Management Inc. bought a new stake in Orthofix Medical in the 2nd quarter valued at $349,000. Institutional investors and hedge funds own 89.76% of the company’s stock.

Trending Headlines about Orthofix Medical

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Engine Capital (a major shareholder) purchased 124,797 shares at an average $12.55 (a ~3.53% increase in its stake), signaling confidence from an activist holder; filing: SEC Filing
• Positive Sentiment: Engine Capital added another 13,061 shares at ~$12.96, a smaller follow-on buy that further increases their total stake — another sign an influential holder is accumulating. SEC Filing
• Neutral Sentiment: Coverage pieces and earnings summaries are reframing the story: analysts and outlets are highlighting margin timing issues and updated 2026 guidance, moving the narrative from near-term margin pressure to longer-term channel optimization. Article
• Neutral Sentiment: Multiple outlet earnings summaries and call write-ups detail that revenue was roughly in line but margins missed, providing context for management’s updated timeline for reaching its 6.5%–7.5% sales CAGR through 2028. Seeking Alpha
• Negative Sentiment: Q4 EPS missed materially (reported -$0.06 vs. $0.44 expected), which caused an immediate share pullback and remains the principal near-term negative catalyst. Earnings Miss
• Negative Sentiment: Analysts cut price targets after results: Canaccord trimmed its target from $24 to $20 but maintained a buy rating, and Barrington lowered its target from $18 to $17 (outperform). These reductions limit near-term upside expectations despite positive ratings. Benzinga

Orthofix Medical Company Profile

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.